Meridian Bioscience (NASDAQ:VIVO) Given Coverage Optimism Rating of 0.09

Headlines about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Meridian Bioscience earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.6845833066133 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern’s scoring:

A number of research firms have recently commented on VIVO. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub cut Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Canaccord Genuity increased their price objective on Meridian Bioscience from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $14.75.

Shares of Meridian Bioscience (NASDAQ:VIVO) opened at 13.75 on Friday. The stock has a market cap of $580.29 million, a price-to-earnings ratio of 27.50 and a beta of 0.89. The firm’s 50-day moving average price is $14.84 and its 200-day moving average price is $13.99. Meridian Bioscience has a 12-month low of $10.75 and a 12-month high of $19.85.

Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company had revenue of $50.14 million for the quarter, compared to the consensus estimate of $49.13 million. During the same period last year, the firm posted $0.21 EPS. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. On average, analysts forecast that Meridian Bioscience will post $0.67 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 17th. Stockholders of record on Monday, August 7th will be given a $0.125 dividend. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.64%. Meridian Bioscience’s payout ratio is currently 98.04%.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-meridian-bioscience-nasdaqvivo-stock-price-updated.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Insider Buying and Selling by Quarter for Meridian Bioscience (NASDAQ:VIVO)

What are top analysts saying about Meridian Bioscience Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Meridian Bioscience Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit